Active, not recruitingPhase 2NCT04205409

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Rahul Banerjee, MD
Fred Hutch/University of Washington Cancer Consortium
Intervention
Nivolumab(biological)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2029

Study locations (1)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04205409 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials